Meeting
2023 ASCO Annual Meeting
Early ctDNA reduction may identify patients with stable disease and long OS on tebentafusp.
Authors
Dan Feng
Memorial Sloan Kettering Cancer Center, New York, NY
Dan Feng , Laura Collins , Margaret K. Callahan , Ryan J. Sullivan , Sophie Piperno-Neumann , Paul D. Nathan , Jessica Cecile Hassel , Howard Goodall , Chris Holland , Koustubh Ranade , Alexander Noor Shoushtari
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Other Melanoma/Skin Cancers
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9589)
DOI
10.1200/JCO.2023.41.16_suppl.9589
Abstract #
9589
Poster Bd #
352
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Association between clinical and disease characteristics and detectable or undetectable baseline ctDNA in patients with metastatic uveal melanoma.
First Author: Paul D. Nathan
Poster
2024 ASCO Annual Meeting
Comparison of clinical outcomes of stable disease with confirmed tumor reduction and RECIST partial response for tebentafusp in metastatic uveal melanoma (mUM).
First Author: Alexandra Ikeguchi
Poster
2023 ASCO Annual Meeting
Survival outcomes associated with liver-directed therapies in patients with metastatic uveal melanoma.
First Author: Michael M Caplan
Poster
2022 ASCO Annual Meeting
Analysis of the effect of systemic corticosteroids on survival from tebentafusp in a phase 3 trial of metastatic uveal melanoma.
First Author: Alexandra Ikeguchi